sitagliptin sandoz
sandoz d.d. - sitagliptinas - plėvele dengtos tabletės - 100 mg - sitagliptin
sitagliptin wörwag pharma
wörwag pharma gmbh & co. kg - sitagliptinas - plėvele dengtos tabletės - 25 mg - sitagliptin
sitagliptin wörwag pharma
wörwag pharma gmbh & co. kg - sitagliptinas - plėvele dengtos tabletės - 50 mg - sitagliptin
sitagliptin wörwag pharma
wörwag pharma gmbh & co. kg - sitagliptinas - plėvele dengtos tabletės - 100 mg - sitagliptin
sitagliptin/metformin hydrochloride grindeks
as grindeks - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - metformin and sitagliptin
sitagliptin/metformin hydrochloride grindeks
as grindeks - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/1000 mg - metformin and sitagliptin
sitagliptin/metformin hydrochloride teva
teva gmbh - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - metformin and sitagliptin
sitagliptin/metformin hydrochloride teva
teva gmbh - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/1000 mg - metformin and sitagliptin
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir fiziniais pratimais pacientams, nepakankamai kontroliuojama, jų maksimali toleruojama dozė metforminas ir sulfonilkarbamido dariniai. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
sitagliptin/metformin hydrochloride sandoz
sandoz d.d. - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - metformin and sitagliptin